Start Date
July 2, 2020
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2021
ADP-A2M4 in combination with pembrolizumab.
Single infusion of autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced cells by a single intravenous infusion Repeat doses of pembrolizumab every 3 weeks. Dose: 200mg
West Virginia University Cancer Institute, Morgantown
Vanderbilt-Ingram Cancer Center, Nashville
Karmanos Cancer Insitute, Detroit
University of Kansas Medical Center, Kansas City
MD Anderson Cancer Center, Houston
Mayo Clinic Phoenix, Phoenix
University of California San Diego, San Diego
Providence Cancer Institute Franz Head and Neck Clinic, Portland
Lead Sponsor
Adaptimmune
INDUSTRY